1048. Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • Endocarditis poster presentaion.pdf (375.3 kB)
  • Background:

    Beta-hemolytic streptococci (BHS) are an uncommon cause of infective endocarditis (IE). The aim of this study is to describe the clinical features and outcomes of patients with beta-hemolytic streptococcal infective endocarditis in a large multi-national cohort, and compare them to patients with oral Viridans IE, a more common cause of IE.

    Methods:

    The International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) is a large multi-national database that recruited patients with IE prospectively using a standardized data set. 64 sites in 28 countries reported patients prospectively using a standard case report form (CRF) developed by ICE collaborators. Patients with BHS IE were compared to patients with IE due to Oral Viridans Streptococci (OVS).

    Results:

    Among 1336 cases of streptococcal IE, 823 (62%) were caused by OVS and 147 (11%) by BHS. The majority of patients in both groups belonged to the male gender and had similar median age. Among the predisposing conditions, congenital heart disease and native valve predisposition were more commonly associated with OVS IE than with BHS IE (p<0.005). The presence of endocavitary cardiac device is associated more with BHS IE than with OVS IE (p=0.026). BHS were more likely to be penicillin-susceptible than OVS (p=0.001). Clinically, patients with BHS IE are more likely to present acutely (p<0.005), and with fever (p=0.024). BHS IE is more likely to be complicated by stroke (p<0.005) and other systemic embolism (p<0.005). The overall in-hospital mortality of BHS IE was significantly higher than that of OVS IE (p=0.001). The independent factors associated with in-hospital mortality for beta-hemolytic streptococcal IE were age, per 1-year increment (OR 1.044; CI 1.014-1.075; p=0.004) and prosthetic valve IE (OR 3.029; CI 1.171-7.837; p=0.022). The complications associated with a higher in-hospital mortality were CHF (OR 2.513; CI 1.074-5.879; p=0.034), especially CHF NYHA III or IV (OR 4.136; CI 1.707-10.025; p=0.002), and Stroke (OR 3.198; CI 1.343-7.619; p=0.009).

    Conclusion:

    Our findings suggest that BHS IE is an aggressive disease characterized by an acute presentation. It is associated with a significant rate of complications and a high rate of in-hospital mortality. This underlines the importance of early surgery to prevent the progression of disease.

    Nuria Fernandez-Hidalgo, MD, Hospital Vall D'hebron, Barcelona, Spain, Amal Gharamti, MD, Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon, MarĂ­a Luisa Aznar, MD, Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain, Vivian H. Chu, MD, Duke University Medical Center, Durham, NC, Hussein Rizk, MD, Cairo University, Cairo, Egypt and Zeina Kanafani, MD, Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Disclosures:

    N. Fernandez-Hidalgo, None

    A. Gharamti, None

    M. L. Aznar, None

    V. H. Chu, None

    H. Rizk, None

    Z. Kanafani, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.